Abstract
For the purpose of enhancing the anticancer potency of docetaxel, a novel excipient, cholesterol-PEG-folate (α-(3.beta) cholest-5-en-3-ω-folic acid-poly (oxy-1, 2-ethanediyl)), was synthesized and used for the preparation of liposomes (folate-conjugated PEG-liposomes). The in vitro release properties, in vitro cytotoxicity, in vivo pharmacokinetics and distribution, as well as in vivo potency of the liposomes were evaluated. These liposomes were able to control the release of the loaded drug. Docetaxel-loaded, folate-conjugated PEG-liposomes were more cytotoxic to MCF-7 cells than ordinary PEG-liposomes. The pharmacokinetic parameters of folate-conjugated PEG-liposomes were studied in rats. Compared to docetaxel solution, the folate-conjugated PEG-liposomes enhanced the t(1/2) of docetaxel by 6.74-fold. The biodistributions of docetaxel in the heart, brain and kidneys decreased when delivered in liposomes. The folate-conjugated PEG-liposomes could significantly enhance tumor accumulation of docetaxel and antitumor activity in tumor-bearing mice (p<0.05). The precent results indicate that these folate-conjugated PEG-liposomes might enhance the potency while preventing the side effects of docetaxel.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
